Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
- PMID: 15232330
- DOI: 10.1097/01.jcp.0000132448.65972.d9
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
Abstract
Context: Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder.
Objective: To evaluate duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on improvement of emotional and painful physical symptoms.
Design: Randomized, double-blind, evaluation of duloxetine at 40 mg/d (20 mg twice daily) and 80 mg/d (40 mg twice daily) versus placebo and paroxetine 20 mg/d in depressed outpatients.
Main outcome measures: The primary efficacy measure was the 17-item Hamilton Depression Rating Scale. Visual Analog Scales for pain, Clinical Global Impression of Severity, Patient's Global Impression of Improvement, and Quality of Life in Depression Scale were also used. Safety was evaluated by assessing discontinuation rates, adverse event rates, vital signs, and laboratory tests.
Results: Duloxetine 80 mg/d was superior to placebo on mean 17-item Hamilton Depression Rating Scale total change by 3.62 points (95% CI 1.38, 5.86; P = 0.002). Duloxetine at 40 mg/d was also significantly superior to placebo by 2.43 points (95% CI 0.19, 4.66; P = 0.034), while paroxetine was not (1.51 points; 95% CI -0.55, 3.56; P = 0.150). Duloxetine 80 mg/d was superior to placebo for most other measures, including overall pain severity, and was superior to paroxetine on 17-item Hamilton Depression Rating Scale improvement (by 2.39 points; 95% CI 0.14, 4.65; P = 0.037) and estimated probability of remission (57% for duloxetine 80 mg/d, 34% for paroxetine; P = 0.022). The only adverse event reported significantly more frequently for duloxetine 80 mg/d than for paroxetine was insomnia (19.8% for duloxetine 80 mg/d, 8.0% for paroxetine; P = 0.031). Hypertension incidence was not affected by any treatment.
Conclusion: Duloxetine therapy was efficacious for emotional and physical symptoms of depression, with a selective serotonin reuptake inhibitor-like profile of side effects.
Copyright 2004 Lippincott Williams and Wilkins
Similar articles
-
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70. doi: 10.1016/j.euroneuro.2004.01.002. Eur Neuropsychopharmacol. 2004. PMID: 15589385 Clinical Trial.
-
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.J Psychiatr Res. 2005 Jan;39(1):43-53. doi: 10.1016/j.jpsychires.2004.04.011. J Psychiatr Res. 2005. PMID: 15504423 Clinical Trial.
-
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.J Clin Psychiatry. 2002 Apr;63(4):308-15. doi: 10.4088/jcp.v63n0407. J Clin Psychiatry. 2002. PMID: 12000204 Clinical Trial.
-
Venlafaxine extended-release: a review of its use in the management of major depression.CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review.
-
Duloxetine: a review of its use in the treatment of generalized anxiety disorder.CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. CNS Drugs. 2009. PMID: 19480470 Review.
Cited by 61 articles
-
Modified reference based imputation and tipping point analysis in the presence of missing data due to COVID-19.Contemp Clin Trials. 2021 Nov;110:106575. doi: 10.1016/j.cct.2021.106575. Epub 2021 Sep 28. Contemp Clin Trials. 2021. PMID: 34597836 Free PMC article.
-
Design and conduct of confirmatory chronic pain clinical trials.Pain Rep. 2020 Dec 18;6(1):e845. doi: 10.1097/PR9.0000000000000854. eCollection 2021 Jan-Feb. Pain Rep. 2020. PMID: 33511323 Free PMC article. Review.
-
A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine.Front Psychiatry. 2020 Oct 23;11:554899. doi: 10.3389/fpsyt.2020.554899. eCollection 2020. Front Psychiatry. 2020. PMID: 33192668 Free PMC article.
-
Effects of antidepressants on QT interval in people with mental disorders.Arch Med Sci. 2020 May 29;16(4):727-741. doi: 10.5114/aoms.2019.86928. eCollection 2020. Arch Med Sci. 2020. PMID: 32542073 Free PMC article. Review.
-
Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.Neuropsychopharmacology. 2020 Feb;45(3):553-560. doi: 10.1038/s41386-019-0523-4. Epub 2019 Sep 14. Neuropsychopharmacology. 2020. PMID: 31521062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
